ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveWe evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability.
methodsUsing MarketScan (2011-2021), we identified offspring born to mothers with chronic inflammatory diseases. TNFi exposure was defined as at least one filled prescription during pregnancy, further subdivided by trimesters and placental transfer. The event of interest was the time to first hospitalization with infection in the offspring's first year of life. We estimated associations between TNFi exposure and infection risk using multivariable Cox proportional hazards models, adjusting for maternal demographics, disease type, comorbidities, pregnancy complications, and drug exposure.
resultsWe identified 56,866 offspring; 3,711 (6.5%) were exposed to TNFi during pregnancy. Overall, the association of TNFi exposure with the risk of serious infections vs unexposed offspring was not statistically significant (hazard ratio [HR] 0.85; 95% confidence interval [CI] 0.68-1.07). However, offspring exposed during the third trimester had a 70% higher risk of serious infections than those exposed only in the first and/or second trimesters (HR 1.70; 95% CI 0.96-3.01). Additionally, we observed an increased risk with exposure to any TNFi with high placental transfer ability (infliximab, adalimumab, golimumab) overall (HR 1.49; 95% CI 0.83-2.69) and during the third trimester (HR 1.30, 95% 0.65-2.61), compared to only low placental transfer TNFi (certolizumab, etanercept), though both HR were not statistically significant.
conclusionOverall, TNFi exposure was not associated with serious infections; exploratory signals by timing and placental transfer were imprecise and require confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.